Related Experiment Video
Updated: May 4, 2026
03:36
Development of Compendium for Esophageal Squamous Cell Carcinoma
Published on: April 12, 2024
974
Eosinophilia in routine blood samples as a biomarker for solid tumor development - A study based on The Copenhagen
Christen Lykkegaard Andersen1, Volkert Dirk Siersma, Hans Carl Hasselbalch
1Department of Hematology, Roskilde University Hospital , Denmark.
Acta Oncologica (Stockholm, Sweden)
|December 24, 2013
Summary
Eosinophilia, a type of white blood cell elevation, is linked to a lower risk of breast cancer but a higher risk of bladder cancer. Further research is needed to understand eosinophils
Area of Science:
- Oncology
- Hematology
- Epidemiology
Background:
- Eosinophilia may indicate early malignancy and host anti-tumor responses.
- The link between eosinophilia and solid tumor development lacks epidemiological investigation.
Purpose of the Study:
- To prospectively investigate eosinophilia in routine blood samples as a potential biomarker for solid tumor development.
Main Methods:
- Utilized the Copenhagen Primary Care Differential Count (CopDiff) Database (2000-2007) with 356,196 individuals.
- Categorized eosinophil counts into no, mild, or severe.
- Linked to the Danish Cancer Registry to identify solid tumors within three years post-blood count, using multivariable logistic regression.
Main Results:
- Mild eosinophilia was associated with a significantly lower risk of breast cancer (OR = 0.51).
- Eosinophilia severity correlated with an increased risk of bladder cancer (mild: OR = 2.27; severe: OR = 2.62).
- No significant associations were found for other solid cancers.
Conclusions:
- Routine blood eosinophil counts are associated with differential risks for specific solid tumors: decreased for breast cancer, increased for bladder cancer.
- Further preclinical studies are essential to elucidate the role of eosinophils in carcinogenesis, distinguishing between tumor immune surveillance and neoplastic progression.
